Meeting
2014 ASCO Annual Meeting
RANKL circulating levels in the evaluation of bone response in breast cancer (BC) patients.
Authors
Toni Ibrahim
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) s.r.l., IRCCS - Osteoncology and Rare Tumors Center, Meldola, Italy
Toni Ibrahim , Laura Mercatali , Marianna Ricci , Emanuela Scarpi , Rossana Ricci , Alberto Bongiovanni , Venetia Zavoiu , Nada Riva , Sebastiano Calpona , Chiara Liverani , Devil Oboldi , Elena Amadori , Federico La Manna , Alessandro De Vita , Flavia Foca , Erica Gunelli , Manuela Monti , Patrizia Serra , Dino Amadori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Other
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11128)
DOI
10.1200/jco.2014.32.15_suppl.11128
Abstract #
11128
Poster Bd #
410
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).
First Author: P. Hadji
Poster
2012 Breast Cancer Symposium
Correlation of receptor activator of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657).
First Author: Jiali Li
Poster
2011 ASCO Annual Meeting
Circulating levels of RANK/RANKL and OPG in patients with bone metastasis treated with zoledronic acid: A prospective study.
First Author: T. Ibrahim
Poster
2022 ASCO Annual Meeting
A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study).
First Author: Nizar Bhulani